Kuros Biosciences AG (0RHR.L) • LSE
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold 0RHR.L in your mock portfolio yet.
The company is currently loss-making, as indicated by a negative EPS and thus a negative PE ratio. This suggests that, on a trailing basis, Kuros Biosciences AG has not yet reached sustainable profitability, which is typical for earlier-stage biotech but still a financial risk. Without evidence of a clear path to positive earnings, the financial profile leans negative for equity holders in the near term.
The stock has sold off 17.3% over the last month, indicating recent negative momentum or sentiment. However, the current price of $17.94 is dramatically above the 200-day moving average of $4.58, suggesting that, despite the recent pullback, the longer-term trend has been strongly upward, likely driven by prior positive news or re-rating. Without explicit RSI data, the technical picture is mixed: elevated versus long-term averages but under short-term pressure.
Social media and online presence metrics are modest in absolute terms but show slow, steady growth. The small increases in Instagram and YouTube followers and a moderate LinkedIn following suggest a niche but gradually expanding awareness, more consistent with a specialized B2B/biotech profile than a consumer-facing brand. These signals are not strong enough on their own to materially shift the stock outlook, but they do not point to deteriorating engagement.
Overall, Kuros Biosciences AG presents a high-risk profile with negative earnings and recent share price weakness following a strong multi-month run. The lack of profitability and reliance on future expectations, combined with recent downward price momentum, tilt the near-term outlook toward a cautious, bearish stance. Modestly positive alternative data and a still-elevated price versus the 200-day average prevent an outright negative structural view, but they do not offset the core financial risks.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started